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Featured Application: This work finds its key application in medical diagnosis and prognosis.
It paves the way to robust automatic HER2 classification using only H&E slides. This approach
possibly avoids the additional costs and time spent IHC testing, providing an indication of the
IHC result.
Abstract: Human epidermal growth factor receptor 2 (HER2) evaluation commonly requires
immunohistochemistry (IHC) tests on breast cancer tissue, in addition to the standard haematoxylin
and eosin (H&E) staining tests. Additional costs and time spent on further testing might be avoided
if HER2 overexpression could be effectively inferred from H&E stained slides, as a preliminary
indication of the IHC result. In this paper, we propose the first method that aims to achieve this goal.
The proposed method is based on multiple instance learning (MIL), using a convolutional neural
network (CNN) that separately processes H&E stained slide tiles and outputs an IHC label. This CNN
is pretrained on IHC stained slide tiles but does not use these data during inference/testing. H&E tiles
are extracted from invasive tumour areas segmented with the HASHI algorithm. The individual
tile labels are then combined to obtain a single label for the whole slide. The network was trained
on slides from the HER2 Scoring Contest dataset (HER2SC) and tested on two disjoint subsets of
slides from the HER2SC database and the TCGA-TCIA-BRCA (BRCA) collection. The proposed
method attained 83.3% classification accuracy on the HER2SC test set and 53.8% on the BRCA test set.
Although further efforts should be devoted to achieving improved performance, the obtained results
are promising, suggesting that it is possible to perform HER2 overexpression classification on H&E
stained tissue slides.
Keywords: weakly-supervised learning; HER2; breast cancer
1. Introduction
Breast cancer (BCa) is the most commonly diagnosed cancer and the leading cause of
cancer-related deaths among women worldwide. However, over the most recent years, despite the
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increasing incidence trends, the mortality rate has significantly decreased. Among other factors,
this improvement results from better treatment strategies that can be delineated from the assessment
of histopathological characteristics [1,2].
The analysis of tissue sections of cancer specimens (Figure 1) obtained by preoperative biopsy,
commonly starts with haematoxylin and eosin (H&E) staining, which is usually followed by
immunohistochemistry (IHC), a more advanced staining technique, used to highlight the presence of
specific protein receptors [3]. In fact, according to the current guidelines [4], Human epidermal growth
factor receptor 2 (HER2) quantification must be routinely tested in all patients with invasive BCa,
recurrence cases, and metastatic tumours. The overexpression of this receptor is observed in 10–20% [4]
of BCa cases and has been associated with aggressive clinical behaviour and poor prognosis [5].
However, patients diagnosed with HER2-positive BCa have a better response to targeted therapies
and consequent improvements in healing and overall survival, which emphasizes the importance of
an accurate evaluation of HER2 status [5,6].
The current guidelines [7], revised by the American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP), in 2018, indicate the following scoring criteria for HER2 IHC:
– IHC 0+: no staining or incomplete, barely perceptible membrane staining in 10% of tumour cells
or less;
– IHC 1+: incomplete, barely perceptible membrane staining in more than 10% of tumour cells;
– IHC 2+: weak to moderate complete membrane staining in more than 10% of tumour cells;
– IHC 3+: circumferential, complete, intense membrane staining in more than 10% of tumour cells.
Moreover, cases scoring 0+ or 1+ are classified as HER2 negative, while cases with a score of
3+ are classified as HER2 positive. Cases with score 2+ are classified as equivocal and are further
assessed by in situ hybridization (ISH), to test for gene amplification (see Figure 1). In these cases,
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Figure 1. Schema of the process of BCa HER2 evaluation, involving H&E staining, IHC testing and,
in specific cases, ISH testing. The proposed method aims to evaluate HER2 using only H&E stained
slide images. Image examples were adapted from [8].
At the moment, besides very well differentiated tumours, with low nuclear/cytoplasm area ratio,
which typically are hormonal driven and therefore generally not positive for HER2, there are no
morphological features on H&E slides that allow a reliable prediction of the HER2 status. Therefore,
the standard procedure is to perform an additional immunohistochemical study, with additional
molecular study in case of equivocal results. Despite the efficiency of IHC and ISH, the additional cost
and time spent on these tests might be avoided if all the information needed to infer the HER2 status
could be extracted only from H&E whole slide images (WSI), as a preliminary indication of the IHC
result. However, to the extent of our knowledge, the task of predicting HER2 status on H&E stained
slides has not yet been addressed in the literature, except for a recent challenge: ECDP2020’s HEROHE
Challenge [9].
In this paper we propose a method using a convolutional neural network (CNN), inspired by
multiple-instance learning (MIL), to automatically identify the HER2 status on BCa H&E stained
slides. To deal with the sheer dimensions of the slides, tiles are extracted from the original images
and separately processed by the model, which learns to aggregate the individual tile predictions into
a single, image-wide label. Moreover, to introduce some prior knowledge about the morphology of
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tissue structures into the model, the CNN has been pre-trained with HER2 IHC stained slides (example
in Figure 2a) from the HER2 Scoring Contest (HER2SC) training set [10]. The final architecture was
trained with the H&E stained slides of HER2SC (example in Figure 2b) and tested with a disjoint subset
of H&E stained slides (example in Figure 2c) from the TCIA-TCGA-BRCA (BRCA) collection [11,12].
The code is publicly available in a GitHub repository [13].
(a) (b) (c)
Figure 2. Image examples from used datasets: HER2SC [10] IHC stained slides (a), HER2SC [10] H&E
stained slides (b), BRCA [11,12] H&E stained slides (c). The tile extraction was solely done on tissue,
here denoted by the delineated regions.
2. Related Work
With the advent of WSI over the last decade, a huge amount of tissue slides are routinely scanned
in clinical practice, thereby increasing data availability. Consequently, and along with its important role
in oncological clinical routine, more research opportunities are raised in computer-assisted imaging
analysis, with this new source of “big data” [14]. In fact, due to the high-resolution and complex
nature of this imaging technique, advances in image analysis are required, providing an opportunity
to apply/develop more advanced image processing techniques, as well as machine and deep learning
algorithms. [15].
The analysis of digital images of digital breast pathology can be applied to tackle several
clinical and pathology tasks such as, for example, mitosis detection [16,17], tissue type classification/
segmentation [18–20], cancer grading [21] or histological classification [22,23]. These approaches
commonly use H&E stained slides and, in recent years, have been focused on applying deep learning
techniques to improve the performance of the models and also to take advantage of the increasing
availability of medical data.
Besides H&E staining slides, some authors, such as Oscanoa et al. [24], Mojoy et al. [25],
Jamaluddin et al. [26] have addressed diverse tasks using IHC slides. On the specific task of automatic
breast cancer HER2 classification, the focus of this work, the literature is limited to the work by
Rodner et al. [27], Mukundan [28], and other studies related with the 2016 HER2 Scoring Contest [10].
The common disadvantage of these prior works is requiring IHC staining images to perform HER2
classification, since this modality requires additional cost and time. In contrast, our approach aims
at using the H&E staining slides as the only source of information to obtain the IHC status for
HER2 overexpression.
In order to complete the proposed task, we followed the idea of using a data source as initialization
for the framework, transferring some domain knowledge to the final training. This is a recent trend
that has been applied to medical imaging processing for different purposes, such as cardiac structures
segmentation [29], Alzheimer disease classification [30], radiological breast lesions classification [31]
and even digital pathology classification/segmentation [32].
Despite the growing popularity of digital pathology and the increasing number of publications in
this area, to the extent of our knowledge, the task of predicting HER2 status on H&E stained slides has
not yet been addressed in the literature.
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3. Methodology
The proposed method (Figure 3) comprises a convolutional neural network (CNN), which is
pre-trained for the task of HER2 scoring of tiles extracted from IHC stained slides. The pre-trained
parameters are then transferred to the task of HER2 status prediction on H&E staining slide tiles,
to provide the network with some knowledge of the tissue structures’ appearance. Individual tile
scores are then combined to obtain a single label for the respective slide. The data preprocessing
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Figure 3. The proposed approach for weakly-supervised HER2 status classification on BCa H&E
stained slides.
3.1. Data Preprocessing
3.1.1. IHC Stained Slides
For the IHC stained slides of classes 2+ and 3+, the preprocessing begins with automatic
tissue segmentation with Otsu’s thresholding on the saturation (S) channel of the HSV colour space,
obtaining the regions with more intense staining, that correspond to the HER overexpression areas.
For slides of classes 0+ and 1+, the segmentation consists of simple removal of pixels with the
greatest HSV value (V) intensity, corresponding to background pixels, which do not contain essential
information to the problem. These processes, which are performed at 32× downsampled slides,
return the masks used in tile extraction.
Tiles with size 256 × 256 are extracted from the slide with original dimensions (without
downsampling), provided they are completely within the mask region. These tiles are converted
from RGB to HSL colour space, of which only the lightness (L) channel is used. Each tile inherits
the class from the respective slide (examples in Figure 4a–d), turning the learning task into a
weakly-supervised problem.
(a) (b) (c) (d) (e)
Figure 4. Tile examples extracted from IHC 0+ (a), IHC 1+ (b), IHC 2+ (c), IHC 3+ (d), H&E (e)
slides. Tiles from IHC 2+ and 3+ and H&E slides were obtained by Otsu’s thresholding and the
remaining were obtained by simply removing the pixels with background value. The IHC tiles were
obtained from slides of the HER2SC dataset [10] and the H&E tile was obtained from a slide of the
BRCA dataset [11,12].
3.1.2. H&E Stained Slides
According to the ASCO/CAP guidelines for IHC evaluation, the diagnosis is performed based
only the tumoral region of the slides. Hence, the preprocessing of H&E stained slides begins
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with an automatic invasive tissue segmentation with the HASHI method [18,33] (High-throughput
Adaptive Sampling for whole-slide Histopathology Image analysis), which consists of an adaptive
gradient-based sampling approach that iteratively refines an initial coarse invasive BCa probability
map, from CNN inference.
The algorithm begins with a WSI as input, that is sampled in 100 tiles, each of them being classified
using a CNN-trained model, to obtain the probability of invasive BCa presence. By interpolation
of each tile probability, a heatmap is generated for the entire WSI. Then, the gradient of the map is
calculated and used to prioritize the sampling selection on the next iteration. The process is repeated
during 20 iterations [18].
The method was implemented in the images referred by Cruz-Roa et al. [18] as the test set,
using the original magnification and extracting squared 512 × 512 tiles. Moreover, to exclude eventual
small background zones included in HASHI segmentation, this mask region was intersected with the
segmentation obtained using Otsu’s thresholding on the saturation (S) channel of the HSV colour space.
The final segmentation mask was then used to generate H&E tiles (example in Figure 4e),
extracted and processed accordingly to the methodology described for IHC slides. The number
of tiles per slide varies according to the extent of the tissue region.
3.2. CNN for IHC Tile Scoring
The CNN architecture (Figure 5) consists of four convolutional layers (16, 32, 64 and 128 filters,
respectively, with ReLU activation). The first layer has 5 × 5 square kernels, while the remaining
have 3 × 3 square kernels. Each convolutional layer is followed by one pooling layer (a max-pooling
function without overlap, with kernel 2 × 2). The network is topped with three fully-connected layers,
with 1024, 256, and 4 units, respectively. The first two have ReLU activation, while the third is followed
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Figure 5. Architecture of the implemented convolutional neural network.
3.3. CNN for H&E Stained Slide Classification
The network parameters pre-trained with IHC stained slides were used as initial network weights
for HER2 status classification on H&E stained slides. It is worth mentioning that IHC data is only
used for the network pre-train, and not on the inference/test phase. To achieve a single prediction per
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tile, instead of four (as it was initially trained for on the IHC setting), a soft-argmax activation [34,35]




where β is an adjustment factor which controls the range of the probability map given by the softmax,
s is the tile score array, and i is the index that corresponds to each class.
Having a single value per tile enables the easy sorting of tiles, which is performed before the
aggregation into a single HER2 label. With the HER2 scores of each tile, output by the soft-argmax
activation, tiles are sorted from 3+ to 0+. Then, the 15% highest scores are selected to serve as input to
the aggregation process. This percentage was chosen to limit the information given to the aggregation
network, while still including and barely exceeding the reference 10% of tumour area considered in
the HER2 scoring guidelines.
The score aggregation is performed by a multilayer perceptron (MLP), composed of four layers,
with 256, 128, 64, and 2 neurons, respectively. All layers are followed by ReLU activation, except the
last layer, which is followed by softmax activation. Since the input dimension M of the MLP is fixed
(we set M = 300 in our experimental analysis, to limit memory cost), for images where 15% of the
number of tiles exceeds M, we downsample to 300 using evenly distributed tile selection. In cases
where 15% of the number of tiles is lower than M, tiles are extracted with overlap, to guarantee that M
tiles can be selected. The MLP will process these 300 HER2 scores and output a single HER2 status
label for the respective slide.
4. Experimental Settings
4.1. Data
The dataset is composed of subsets of WSI from two public datasets: the HER2 Scoring Contest
(HER2SC) training set [10] and the TCGA-TCIA-BRCA (BRCA) collection [11,12]. The HER2SC training
set (the subset with available labelling) comprises WSI of sections of 52 cases of invasive BCa stained
with both IHC and H&E (example in Figure 2a,b). From this set, all IHC and H&E stained slides were
used, except 4 H&E excluded because of manual ink markings. The subset from the BRCA dataset
includes 54 H&E stained WSI (example in Figure 2c). All slides have the same original resolution and
are weakly annotated with HER2 status (negative/positive) and score (0+, 1+, 2+, 3+), obtained from
the corresponding histopathological reports.
The IHC stained slides were manually segmented into regions of interest (ROI), using the Sedeen
Viewer software [36]. However, it is noteworthy that these slides were only used for training and,
thus this step is not needed for testing.
The training and validation sets, used for model parameter tuning and optimization, have 40 and
12 IHC slides, respectively. A total of 7591 tiles per class have been extracted for training (30,364 tiles
total) and 624 tiles per class extracted for validation (2496 tiles total), to keep a class balance.
4.2. Training Details
The hyperparameters used during training were empirically set to maximize performance.
The CNN model for IHC tile scoring was randomly initialized and trained using the Adaptive
Moment Estimation (Adam) [37] optimizer (learning rate of 1 × 10−5), to minimize a cross-entropy
loss function, during 200 epochs, with mini-batches of 128 tiles. The soft-argmax used a parameter
β = 1000. The aggregation MLP was trained using the Adam optimizer, with learning rate of 10−5
for 150 epochs and mini-batches of 1 WSI (consisting of soft-argmax scores of the respective 300 tiles),
saving the best considering validation accuracy.
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5. Results and Discussion
5.1. Individual IHC Tile Scoring Results
After training, the model offered 76.8% accuracy (see Table 1). This indicates that the model
was able to adequately discriminate against the IHC tiles between the four classes. This model was
subsequently transferred for HER2 scoring in tiles from H&E slides.
Table 1. Confusion matrix of the CNN for HER2 scoring in IHC tiles.
True Class
0 1 2 3
0 490 132 2 0
1 176 384 64 0
2 45 159 419 1
Prediction
3 0 0 1 623
5.2. Invasive Tumor Tissue Segmentation
Tiles from H&E WSI are extracted from the intersection area between the HASHI-based invasive
tumour segmentation and the Otsu-based tissue segmentation. The HASHI segmentation method
was trained on the BRCA data reported as the test set by Cruz-Roa et al. [18], with 179 WSI on their
original magnification. The results were comparable to the original paper (see examples in Figure 2)
and were further evaluated by a pathology specialist, who confirmed the adequacy of the invasive
tumour segmentation results.
5.3. Slide Scoring
On the HER2SC test set, this method achieved an F1-score of 86.7% and a weighted accuracy of
83.3% (see Table 2). Despite the small size of this test set, the proposed method was able to correctly
classify all positive WSI and only misclassify one negative sample as positive. In this context, one might
consider this a desirable behaviour, as false positives are less impactful than false negatives.
When tested on the BRCA test set, this method achieved an F1-score of 21.5% and a weighted
accuracy of 53.8% (see Table 2). The method retains the behaviour presented in HER2SC, preferring to
err on the side of false positives than the alternative. On the other hand, the performance metrics on
BRCA differ considerably from those obtained on HER2SC. While the method was trained on HER2SC
data, which is expected similar to the test data, the WSI of the BRCA dataset presents some notable
differences. These slides have a greater extent of tissue, which generates more tiles per image and
impacts the distribution of the scores, which may influence the method’s behaviour.
Table 2. H&E HER2 status classification results of the proposed method on the HER2SC and BRCA
test sets.
Accuracy F1-Score Precision Recall
HER2SC 83.3% 86.7% 89.6% 87.5%
BRCA 53.8% 21.5% 81.2% 31.5%
The evaluation results in single-database (HER2SC) and cross-database (BRCA) settings show the
potential of the proposed method in standard and more challenging situations. However, the method
appears to be dataset-dependent: it performed much better in conditions similar to the training.
This should be addressed with additional efforts regarding domain adaptation.
The other shortcomings of the method appear to be related to the invasive tumour tissue
segmentation and the individual tile scoring network, which could be improved with additional
data and more accurate ground truth information. With these additional efforts, the proposed method
could offer robust weakly-supervised WSI HER2 classification without IHC information.
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5.4. Ablation Study
Considering the lack of literature methods, to perform a benchmark, an ablation study was
performed to confirm the capabilities of the proposed method. Experiments were conducted without
IHC individual tile scoring CNN initialization, and using alternative statistical methods for individual
tile score aggregation instead of MLP (median and mean), as can be seen in Tables 3 and 4. The results
show that these alternatives are, in most settings, less adequate for the task at hand.
It is noteworthy that the median and mean-based aggregation are followed by a conversion
to binary classes (0+ and 1+ are considered negative, while 2+ and 3+ are considered positive),
since tiles have four possible labels. According to the guidelines, 2+ cases can be either negative or
positive, but in an uncertain diagnosis scenario, it is preferable to classify them as positive.
Table 3. Results on the HER2SC test set.
Method Accuracy F1-Score Precision Recall
MLP Aggregation:
proposed method 83.3% 86.7% 89.6% 87.5%
w/out pretrained CNN weights 62.5% 48.1% 39.1% 62.5%
Median Aggregation:
w/pretrained CNN weights 50.0% 43.3% 78.6% 50.0%
w/out pretrained CNN weights 62.5% 48.1% 39.1% 62.5%
Mean Aggregation:
w/pretrained CNN weights 50.0% 43.3% 78.6% 50.0%
w/out pretrained CNN weights 62.5% 48.1% 39.1% 62.5%
Table 4. Results on the BRCA test set.
Method Accuracy F1-Score Precision Recall
MLP Aggregation:
proposed method 53.3% 21.5% 81.2% 31.5%
w/out pretrained CNN weights 50.0% 60.3% 51.8% 72%
Median Aggregation:
w/pretrained CNN weights 50.0% 12.3% 7.8% 28.0%
w/out pretrained CNN weights 52.2% 63.5% 66.5% 72.0%
Mean Aggregation:
w/pretrained CNN weights 50.0% 12.3% 7.8% 28.0%
w/out pretrained CNN weights 52.2% 63.5% 66.5% 72.0%
6. Conclusions
In this work, a framework is proposed for the weakly supervised classification of HER2
overexpression status on H&E stained BCa WSI. The proposed approach integrates a CNN trained for
HER2 scoring of individual H&E stained slide tiles, initialized with the network parameters pre-trained
with data from IHC stained images. The objective of this initialization is to transfer some domain
knowledge to the final training. The individual scores are aggregated on a single prediction per slide,
returning the HER2 status label.
Tested with the BRCA data subset, the proposed method attained suitable performance.
These preliminary results indicate that it is possible to accurately infer BCa HER2 status solely from
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H&E stained slides. The results of an ablation study suggest that the proposed method with MLP tile
score aggregation is more promising than simpler aggregation methods (mean or median).
Despite these results, further efforts should be devoted to performance improvements in this task.
Firstly, the training of the tile HER2 scoring CNN and the aggregation MLP could be integrated into
a single optimization process to achieve better performance. On the other hand, the aggregation of
individual scores could use tile locations to take spatial consistency into account. Finally, the knowledge
embedded in the networks through the pre-trained parameters could be better seized if input H&E
tiles could be previously converted into IHC (possibly using generative adversarial models).
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